Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2985012 | 1.00 | F10 (0.61) | F10F2 | |
| SCHEMBL3646789 | 0.87 | F10 (0.48) | F10F2 | |
| SCHEMBL2992841 | 0.86 | F10 (0.51) | F10 | |
| SCHEMBL2992839 | 0.86 | F10 (0.51) | F10 | |
| SCHEMBL2191043 | 0.86 | F10 (0.63) | F10F2 | |
| SCHEMBL2191033 | 0.86 | F10 (0.63) | F10F2 | |
| SCHEMBL2986735 | 0.86 | F10 (0.56) | F10F2 | |
| SCHEMBL2986738 | 0.86 | F10 (0.56) | F10F2 | |
| SCHEMBL5473752 | 0.83 | F10 (0.62) | F10F2 | |
| SCHEMBL2998636 | 0.80 | F10 (0.59) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184767-A1 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | ROHRIG SUSANNE | 2010-07-22 | — | — | US | disclosed |
| US-20100184767-A1 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | ROHRIG SUSANNE | 2010-07-22 | — | — | US | disclosed |
| US-20100184767-A1 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | ROHRIG SUSANNE | 2010-07-22 | — | — | US | disclosed |
| WO-2008155034-A1 | SUBSTITUTED OXAZOLIDINONES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184767-A1 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | XDH, OXA1L, PPOX | F10 391/4885F2 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.